Extracts of ginseng species show antihyperglycemic activity. We evaluated the inhibitory effects of diabetic complications for Korean Red Ginseng (KRG), which is enriched in ginsenosides using Otsuka Long-Evans Tokushima Fatty (OLETF) rats. The animals were divided into one of four groups (n ¼ 6w9): LongeEvanseTokushimaeOtsuka rats (control rats), OLETF rats, rats given 200 mg/kg KRG, and rats given 400 mg/kg KRG. We examined the protective potential of KRG against type 2 diabetic illnesses. The results exhibited that KRG showed significant antihyperglycemic and antioxidative effects in KRG-treated OLETF rats. And, our results proposed the amelioration of cardiac function through normalized ejection fraction, fractional shortening, and vascular reactivity. Furthermore, histopathological abnormalities in the OLETF rats were prevented by KRG treatment.
The predominance of diabetes has been predicted to increase to 4.4% in 2030. This could lead to an increase of diabetic cardiovascular complications [1] . However, currently, there are no clearly established remedy for diabetic complication. Traditionally, ginseng (Panax ginseng Meyer) is used as an important herbal medicine in Far East Asia. In general, the major biological activities of Korean Red Ginseng (KRG) are known to include the alleviation of vascular dysfunction, antioxidant effects, and the cardiac protection [2e4] . Yet, there is no a sure proof presenting the potentials for cardiovascular effect of KRG against type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. In the present study, we use KRG extract manufactured by Korea Ginseng Corporation (Daejeon, Korea) from the roots of 6-year-old fresh ginseng cultivated in Korea. Six male LongeEvanseTokushimaeOtsuka (LETO) rats and 27 OLETF rats (Central Lab. Animal Inc., Korea), weighting about 200 AE 10 g, were used for one set of experiment agreeing to the "Guideline for Institutional Animal Care and Use Committees" of Chonbuk National University (Jeonju, Korea). Animals were randomly allocated into LETO rats, normal group, OLETF rats, OLETFþ200 mg/kg KRG-treated group, and OLETFþ400 mg/kg KRG-treated group. Administration of 200 mg/kg and 400 mg/kg KRG was conducted for 180 consecutive days (Fig. 1 ), and feed intake and plasma glucose were measured twice a month throughout 180 days. At the end of the experimentation, antioxidant analysis, echocardiography recording, and vascular reactivity were examined. Data are expressed as meanAEstandard error of mean. Comparison between the LETO, OLETF, and KRG experimental groups were analyzed by Student t tests and one-way analysis of variance. The probability values less than 0.05 were regarded as significant statistically.
As a result, compared with OLETF group, body weight gain was lesser in the 200 mg/kg and 400 mg/kg KRG group after 180 days of treatment (data not shown). In this respect, feed consumption of OLETF group was significantly increased than LETO after 75 days. However, administration of 200 mg/kg/day and 400 mg/kg KRG produced a significant decrease after 3 months in a dosedependent manner (*p < 0.05, **p < 0.01 compared with OLETF, Fig. 2A ). And, plasma glucose levels were significantly increased in OLETF control. But, the administration of KRG inhibited the elevation of fasting blood glucose with dose-dependent manner (*p < 0.05, ** p < 0.01, Fig. 2B ). The results indicated that 400 mg/ kg KRG is more effective than 200 mg/kg in plasma glucose levels.
And, using echocardiography, we have assessed the effect of KRG on cardiac function by evaluating an ejection fraction (EF) for the assessment of left ventricle systolic function and a fractional shortening (FS), another index for ventricle systolic function [5, 6] . Currently, it was well known that EF is the most precious function index for clinical application [7] . As revealed in Fig. 3 in all groups were stained with normal hematoxylin and eosin stain. Compared with the LETO (Fig. 4A(a) ), the dilated aorta in OLETF group showed an infiltration of inflammatory cells, thickening of intima, and extensive destruction (arrows, Fig. 4A(b) ). In contrast, an infiltration of narrow thickening and a few extensive destructions of the medial elastic lamellae were observed in 200 mg/kg and 400 mg/kg KRG-treated group after 180 days (arrows, Fig. 4A(c) and (d) , respectively). In succession, the contractile response of aorta was examined in all groups. The contractility for norepinephrine were represented as the percentage of the activity to the maximal contraction in 70 mM KCl. Cumulative dose of 10 À10 to 10 À5 M norepinephrine resulted in dose-dependent contractions in each group. In contraction response by 10 À10 to 10 À5 M norepinephrine, the maximum contraction or dilation value (V max ) of OLETF group were significantly increased than those of LETO control group, OLETFþ200 mg/kg KRG, and OLETFþ400 mg/kg KRG groups (Fig. 4B) . Namely, the V max were 69.37 AE 7.54%, 100.62 AE 9.75%, 97.84 AE 10.56%, and 89.72.490 AE 9.95% for LETO, OLETF control, OLETFþ200 mg/kg KRG, and OLETFþ400 mg/kg KRG groups, respectively (*p < 0.05, **p < 0.01 compared with OLETF, Fig. 4A ). Moreover, we evaluated Fig. 4B ). Interestingly, the existing difference between OLETF rats with 200 mg/kg/day and 400 mg/kg KRG was not significant (p > 0.05) at the doses of 1 Â 10 À8 M to 1 Â 10 À5 M carbachol. Finally, these results are supportive of KRG being used as an agent normalizing aorta reactivity. Also, to antioxidant activity, lipid peroxidation was evaluated by quantifying malondialdehyde (MDA) levels, which was measured by the absorbance, spectrophotometrically [8] . As a result, in OLETF rats, there was a significantly increased MDA levels when compared with LETO ( a p < 0.01, Table 1 ). But, administration of 200 mg/kg and 400 mg/kg KRG decreased the MDA level compared with OLETF, dose-dependently ( b p < 0.05, c p < 0.01, Table 1 ). Meanwhile, in the presence of H 2 O 2 , glutathione (GSH)-Px catalyzes reduced GSH. Activity of GSH-Px was analyzed by the analysis of GSH by an enzymatic response [9] . Namely, Activity of GSH-Px was significantly lowered in OLETF control compared to LETO ( a p<0.01, Table 1 ). However, in GSH-Px activity, there was a significant rise in groups administered 200 and 400 mg/kg KRG ( b p < 0.05, c p < 0.01, Table 2 ) compared with OLETF group. In conclusion, our experiment proves primary evidence about the use of KRG against type 2 diabetic model. However, further study has been necessary to examine the biosafety and other additional effectiveness of KRG. Large-scale, potential, and more long-term studies are necessary to prove the right use of KRG against the risk of type 2 diabetic cardiovascular complications.
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